Lupin Gets US FDA Nod for Colonoscopy Prep Tablets, Bags 180-Day Exclusivity

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Lupin Gets US FDA Nod for Colonoscopy Prep Tablets, Bags 180-Day Exclusivity
Overview

Lupin Limited received US FDA approval for its generic Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets. This product, used for colonoscopy preparation, comes with a significant 180-day exclusive first-to-file status, offering a competitive edge in a market worth over $132 million.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

LUPIN GETS US FDA APPROVAL FOR COLPOSCOPY PREP TABLETS

Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets.

Reader Takeaway: US FDA approval and 180-day exclusivity offer a significant market opportunity, but launch execution is key.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.